Our diversified product pipeline includes treatments for hematological and endocrine disorders, cancer and infectious diseases. We intend to commercialize these products independently and through strategic alliances with corporate partners. We use two protein engineering technologies, Site-Specific PEGylation and ImmunoFusion Protein technology to create our proprietary products.
Both technologies increase a protein's effective size and slow its clearance from the body. Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer and infectious disease.
Both technologies increase a protein's effective size and slow its clearance from the body. Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer and infectious disease.
Services
Bolder BioTechnology, Inc. is a clinical stage protein therapeutics company dedicated to providing patients with easier to use, safer, and more cost effective treatments for their disease. Most protein pharmaceuticals require frequent, often daily, dosing, typically by injection. There is a large unmet medical need for innovative protein drugs that do not require frequent administration.
Most protein therapeutics require frequent, often daily injection because they are rapidly broken down and excreted from the body. There is a large unmet medical need for innovative protein drugs that do not require frequent administration. Our products address that need.
We specialize in using site-specific bioconjugation technologies to selectively modify proteins so that they last longer in patients, reducing the need for frequent administration, and in many cases improving product efficacy and safety.These features are attractive to patients and will make our drugs competitive in the marketplace.
We specialize in using site-specific bioconjugation technologies to selectively modify proteins so that they last longer in patients, reducing the need for frequent administration, and in many cases improving product efficacy and safety.These features are attractive to patients and will make our drugs competitive in the marketplace.
Bolder BioTechnology employs Ph. D. Scientists and Research Associates with expertise in the areas of gene cloning, mutagenesis, expression of proteins in bacteria, insect and mammalian cells, bacterial fermentation of recombinant proteins, purification of recombinant proteins from eukaryotic and prokaryotic cells, structural characterization of recombinant proteins, computer-aided molecular modeling, and in vitro mammalian cell assays.
Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer and infectious disease. These products target markets with over $20 billion in annual sales and have clearly defined clinical development paths, which will allow them to be developed cost-effectively.
We encourage our scientists and collaborators to share their research findings through publications in scientific journals and by giving presentations at scientific meetings. Below is a list of publications authored by our scientists and collaborators.
PEGylated G-CSF (BBT-015), GM-CSF (BBT- 007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome.Site-specific protein PEGylation: application to cysteine analogs of recombinant human granulocyte colony-stimulating factor.
PEGylated G-CSF (BBT-015), GM-CSF (BBT- 007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome.Site-specific protein PEGylation: application to cysteine analogs of recombinant human granulocyte colony-stimulating factor.
Reviews
Be the first to review Bolder Biotechnology.
Write a Review
